Compare MPC & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPC | MRNA |
|---|---|---|
| Founded | 1887 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9B | 91.2B |
| IPO Year | 2011 | 2018 |
| Metric | MPC | MRNA |
|---|---|---|
| Price | $411.60 | $223.85 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 18 | 23 |
| Target Price | ★ $461.94 | $158.47 |
| AVG Volume (30 Days) | 2.2M | ★ 13.6M |
| Earning Date | 11-03-2026 | 11-06-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | ★ 31.15 | 21.77 |
| EPS | ★ 45.40 | N/A |
| Revenue | N/A | ★ $19,263,000,000.00 |
| Revenue This Year | $36.26 | $24.04 |
| Revenue Next Year | N/A | $10.63 |
| P/E Ratio | $9.10 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $161.93 | $22.28 |
| 52 Week High | $493.98 | $280.80 |
| Indicator | MPC | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 49.65 |
| Support Level | $364.73 | $181.02 |
| Resistance Level | $431.08 | $254.48 |
| Average True Range (ATR) | 20.29 | 18.70 |
| MACD | -3.47 | -2.26 |
| Stochastic Oscillator | 43.45 | 43.04 |
Marathon Petroleum is a leading integrated downstream and midstream energy company that operates 13 refineries in the Gulf Coast, midcontinent, and West Coast regions of the United States with an aggregate crude oil refining capacity of 3.0 million barrels per day. The company is one of the largest producers of renewable diesel in the US; its Dickinson, North Dakota, facility has the capacity to produce 184 million gallons per year, and its Martinez, California, joint venture facility (a 50/50 partnership with Neste) reached its full capacity of 730 million gallons per year in late 2024. Marathon also owns the general partner and approximately 64% of MPLX LP, a large-cap master limited partnership that owns and operates midstream energy infrastructure and logistics assets.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.